Sanofi, Ventyx
Ventyx gets $27 million investment from Sanofi
Shares in San Diego-based inflammatory diseases specialist Ventyx Biosciences (Nasdaq: VTYX) rose 8.7% to $2.50 yesterday as it announced that French pharma major Sanofi (Euronext: SAN) has agreed to make a $27 million strategic investment in the company]. The closing of the transaction is expected to occur on September 23, 2024.
GlobalData on MSN4d
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m dealUnder the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.
The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...
Zacks.com on MSN3d
VTYX Stock Rises on Strategic Equity Investment Deal With SNYShares of Ventyx Biosciences VTYX gained 7% on Monday after the company announced that it has entered into a $27 million ...
Ventyx’s relationship with Sanofi may not result in the anticipated positive outcomes; potential delays in the enrollment and completion of clinical trials; Ventyx’s dependence on third parties ...
The company also agreed to grant Sanofi an exclusive right of first negotiation with respect to certain VTX3232 program rights. Also Read: Ventyx Biosciences’ Inflammatory Bowel Disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback